Search

Your search keyword '"Clément Korenbaum"' showing total 7 results
Start Over Author "Clément Korenbaum"
7 results on '"Clément Korenbaum"'

1. Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation

Author

Peter Dreger, Paolo Pedrazzoli, Salvatore Siena, Christoph E Heilig, Stefan Fröhling, Massimo Di Nicola, Manuela Badoglio, Myriam Labopin, Simona Secondino, Jürgen Heinz, Emmanuelle Nicolas-Virelizier, Didier Blaise, Clément Korenbaum, Armando Santoro, Mareike Verbeek, William Krüger, Jakob R Passweg, Jose Rifón, Ulrike Koehl, and Christian Chabannon

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background The role of high-dose chemotherapy with autologous stem cell transplantation (ASCT) in the treatment of soft-tissue sarcoma (STS) remains an unsettled issue. Prospective clinical trials failed to prove a benefit of the procedure but were limited by small and heterogeneous patient cohorts. Thus, it is unknown if ASCT may be a valuable treatment option in specific patient subgroups.Methods The purpose of this study was to investigate the value of ASCT according to histological subtype in STS patients who were registered in the European Society for Blood and Marrow Transplantation database between 1996 and 2016.Results Median progression-free (PFS) and overall survival (OS) in the entire cohort of 338 patients were 8.3 and 19.8 months, respectively, and PFS and OS at 5 years were 13% and 25%, respectively. Analysis of outcomes in different subgroups showed that younger age, better remission status before transplantation and melphalan-based preparative regimen were predictive of benefit from ASCT, whereas histology and grading had no statistically significant impact.Conclusions Outcomes after ASCT compared favorably to those of recent trials on conventional chemotherapies and targeted therapies in STS, including histology-tailored approaches. ASCT, thus, should be reinvestigated in clinical trials focusing on defined patient subgroups.

Published
2020
Full Text
View/download PDF

2. A retrospective study of patients treated with by oral anticancer drugs: Impact of pharmacy consultation

Author

Emmanuelle Clou, Antonin Dubois, Julien Gaudas, Hugo Palisson, Kahina Chetouane, Chloé Talarmin, Olivia Meynial, Jacqueline Nguyen, Sandra Assoun, Marc-Antoine Benderra, Dhekra Nasrallah, Adoraction Esteso, Danièle Avenin, Gilles Galula, Djamel Ghebriou, Joseph Gligorov, Ahmed Khalil, Clément Korenbaum, Coralie Prebet, Hervé Foka-Tichoue, Jean-Pierre Lotz, and Isabelle Debrix

Subjects
Pharmacology, Oncology
Published
2022
Full Text
View/download PDF

3. Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation

Author

Stefan Fröhling, Christian Chabannon, Peter Dreger, Jürgen Heinz, William Krüger, José Rifón, Didier Blaise, Salvatore Siena, Simona Secondino, Mareike Verbeek, Ulrike Koehl, Armando Santoro, Paolo Pedrazzoli, Emmanuelle Nicolas-Virelizier, Massimo Di Nicola, Manuela Badoglio, Clément Korenbaum, Myriam Labopin, Christoph E. Heilig, Jakob Passweg, Publica, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), German Cancer Consortium [Heidelberg] (DKTK), Heidelberg University Hospital [Heidelberg], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre International des greffes [CHU Saint-Antoine] (EBMT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Freiburg University Medical Center, Centre Léon Bérard [Lyon], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Service d'Oncologie médicale [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Greifswald University Hospital, Università degli Studi di Milano [Milano] (UNIMI), University Hospital Basel [Basel], Clínica Universidad de Navarra [Pamplona], Fraunhofer Institute for Cell Therapy and Immunology (Fraunhofer IZI), Fraunhofer (Fraunhofer-Gesellschaft), Hannover Medical School [Hannover] (MHH), and Università degli Studi di Pavia

Subjects
Adult, Melphalan, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Transplantation, Autologous, stem cell transplantation, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, Bone Marrow, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Prospective Studies, 030212 general & internal medicine, Original Research, Preparative Regimen, Chemotherapy, business.industry, Soft tissue sarcoma, Hematopoietic Stem Cell Transplantation, Sarcoma, soft-tissue sarcoma, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, Clinical trial, Transplantation, 030220 oncology & carcinogenesis, business, Stammzelltransplantation, high-dose chemotherapy, medicine.drug
Abstract

Background The role of high-dose chemotherapy with autologous stem cell transplantation (ASCT) in the treatment of soft-tissue sarcoma (STS) remains an unsettled issue. Prospective clinical trials failed to prove a benefit of the procedure but were limited by small and heterogeneous patient cohorts. Thus, it is unknown if ASCT may be a valuable treatment option in specific patient subgroups. Methods The purpose of this study was to investigate the value of ASCT according to histological subtype in STS patients who were registered in the European Society for Blood and Marrow Transplantation database between 1996 and 2016. Results Median progression-free (PFS) and overall survival (OS) in the entire cohort of 338 patients were 8.3 and 19.8 months, respectively, and PFS and OS at 5 years were 13% and 25%, respectively. Analysis of outcomes in different subgroups showed that younger age, better remission status before transplantation and melphalan-based preparative regimen were predictive of benefit from ASCT, whereas histology and grading had no statistically significant impact. Conclusions Outcomes after ASCT compared favorably to those of recent trials on conventional chemotherapies and targeted therapies in STS, including histology-tailored approaches. ASCT, thus, should be reinvestigated in clinical trials focusing on defined patient subgroups.

Published
2020
Full Text
View/download PDF

4. Germline Variants in Highly Selected Patients With Prostate Cancer

Author

Patrick R Benusiglio, Clément Korenbaum, and Florence Coulet

Subjects
Oncology, Cancer Research, Prostate cancer, medicine.medical_specialty, Text mining, business.industry, Internal medicine, medicine, MEDLINE, medicine.disease, business, Germline
Published
2019

5. Familial pancreatic adenocarcinoma: A retrospective analysis of germline genetic testing in a French multicentre cohort

Author

Marie Muller, Pascal Hammel, Florence Coulet, William Greenhalf, Angelique Riffault, Sandra Granier, Chrystelle Colas, Olivier Ingster, Meriem Benfoda, Philippe Jonveaux, Melissa Parrin, Vinciane Rebours, Philippe Lévy, Mathias Schwartz, Mickael Mary, Louis de Mestier, Clément Korenbaum, Jérôme Cros, and Nadem Soufir

Subjects
0301 basic medicine, Oncology, Adult, Male, medicine.medical_specialty, endocrine system diseases, 030105 genetics & heredity, medicine.disease_cause, Germline, Cohort Studies, 03 medical and health sciences, Young Adult, CDKN2A, Internal medicine, Genetics, medicine, Genetic predisposition, Humans, Genetic Testing, Genetics (clinical), Genetic testing, Aged, BAP1, medicine.diagnostic_test, business.industry, Carcinoma, Middle Aged, medicine.disease, digestive system diseases, FANCA, Neoplasm Proteins, Pancreatic Neoplasms, 030104 developmental biology, Germ Cells, Adenocarcinoma, Female, Carcinogenesis, business
Abstract

The rate of genetic diagnosis of French patients with familial pancreatic ductal adenocarcinoma (PDAC) is not known. We report germline genetic testing data from 133 index cases meeting criteria for familial pancreatic cancer (FPC) as well as 87 'FPC-like' index cases who did not fulfilled strict FPC definition but were evocative for a PDAC predisposition. The overall rate of genetic diagnosis (in BRCA1, BRCA2, CDKN2A, and ATM genes) was 8.3% in FPC patients and 4.6% in FPC-like patients, consistent with the literature in other populations. Genetic variants were also identified in FANCA and BAP1 genes, as well as in the CDKN2A p12 transcript. This pancreas-specific transcript is a known key player in driving pancreatic oncogenesis. This might be the first described case of a PDAC genetic predisposition due to a variant in this specific transcript.

Published
2019

6. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic

Author

Charlotte Paul, Patrick R. Benusiglio, Jean Pierre Lotz, Erell Guillerm, Florence Coulet, Sophie Geoffron, Roseline Vibert, Sandrine Richard, Joël Ezenfis, Nathalie Chabbert-Buffet, Veronique Byrde, Noémie Basset, Joseph Gligorov, Manon Lejeune, Clément Korenbaum, CCSD, Accord Elsevier, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de Gynécologie-obstétrique et médecine de la reproduction - Maternité [CHU Tenon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Site de recherche intégrée en cancérologie (SiRIC CURAMUS), Institut Universitaire de Cancérologie [Paris] (IUC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service d'Oncologie médicale [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Sud Francilien, Grand Hôpital de l'Est Francilien (GHEF), Service de Génétique Cytogénétique et Embryologie [CHU Pitié-Salpêtrière], Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Gynécologie-obstétrique et médecine de la reproduction - Maternité [CHU Tenon], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Male, Genetic testing, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Breast cancer, 0302 clinical medicine, Pandemic, Young adult, Mastectomy, Genetics (clinical), Neoadjuvant therapy, Aged, 80 and over, Ovarian Neoplasms, 0303 health sciences, medicine.diagnostic_test, BRCA1 Protein, 030305 genetics & heredity, High-Throughput Nucleotide Sequencing, General Medicine, Middle Aged, Neoadjuvant Therapy, 3. Good health, [SDV] Life Sciences [q-bio], DNA-Binding Proteins, 030220 oncology & carcinogenesis, Hereditary Breast and Ovarian Cancer Syndrome, Female, Fanconi Anemia Complementation Group N Protein, Adult, Paris, medicine.medical_specialty, Genetic counseling, Salpingo-oophorectomy, Breast Neoplasms, Genetic Counseling, Article, Young Adult, 03 medical and health sciences, Ovarian cancer, Internal medicine, Genetics, medicine, Humans, Genetic Predisposition to Disease, Pandemics, Aged, BRCA2 Protein, business.industry, COVID-19, medicine.disease, business
Abstract

International audience; Introduction: Mainstreamed genetic testing (MGT) obviates the need for a cancer genetics consultation, since trained oncologists (O) and gynaecologists (G) provide counseling, prescribe testing and deliver results. We report results from our MGT program and emphasize its utility during the COVID-19 lockdown, when cancer genetics clinics had suspended their activity.Methods: An MGT pathway for breast and ovarian cancer (BC/OC) patients was established in Jan-2018 between the Assistance Publique - Hôpitaux de Paris.Sorbonne Université Cancer Genetics team and the Oncology/Gynecology departments at one teaching and two regional hospitals. Trained O + G evaluated patients with the Manchester Scoring System. A 12-point threshold was recommended for testing. Next-generation sequencing of BRCA1, BRCA2, PALB2, RAD51C and RAD51D was performed. Results were delivered to the patient by O/G. Pathogenic variants (PV) carriers were referred to the genetics clinic. Results are reported for the 2nd-Jan-2018 to 1st-June-2020 period. That includes the eight-week COVID-19 lockdown and three-week de-confinement phase 1.Results: Results were available for 231/234 patients. Twenty-eight (12.1%) carried a PV. Of the 27 patients tested during the COVID-19 period, three carried a PV, two in BRCA1 and one in RAD51C. The clinical impact was immediate for the two BRCA1 BC cases undergoing neo-adjuvant chemotherapy, since double mastectomy and salpingo-oophorectomy will now be performed using two-step strategies.Conclusions: MGT guaranteed care continuity in BC/OC patients during the critical phases of the COVID-19 pandemic, with immediate implications for PV carriers. More broadly, we report for the first time the successful implementation of MGT in France.

Published
2020
Full Text
View/download PDF

7. Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumour with an NF1 Mutation Responding to Trametinib: A Case Report

Author

Nadia Hitchen, Matthew Cross, George Laking, Joanna Connor, and Clement Korenbaum

Subjects
malignant peripheral nerve sheath tumour, nf1, trametinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Sporadically occurring malignant peripheral nerve sheath tumours (MPNSTs) can have a variety of genomic alterations including altered NF1, leading to activation of the RAS-RAF-MEK-ERK signalling pathway. Trametinib is an inhibitor of MEK1 and MEK2. Here we present a case of a patient diagnosed with sporadic MPNST with an identified NF1 gene treated successfully with trametinib.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results